TSX runs higher on rate cut expectations
Athira Pharma (NASDAQ: ATHA) has received a reiterated Outperform rating from Mizuho, with a maintained price target of $5.00.
The company announced after market close that its Phase 2 LIFT-AD study for fosgonimeton in patients with mild-to-moderate Alzheimer's disease did not meet primary and secondary efficacy endpoints.
Despite the disappointing results, the treatment, also known as fosgo, was found to be safe and well-tolerated.
The study's lack of efficacy outcomes contrasts with some positive biomarker signals, suggesting potential for the HGF/MET pathway modulator in treating neurodegenerative diseases.
This has provided Athira Pharma with reasons to remain optimistic about the drug's mechanism of action. However, considering the comprehensive data from both the Phase 2 ACT-AD and LIFT-AD studies, there is a high risk that fosgonimeton may be discontinued due to the costs and resources required for further development.
Mizuho's commentary highlighted these mixed results, noting the safety profile and biomarker findings as positive aspects. The firm anticipates further discussions with Athira Pharma to gain additional insights into the company's plans for fosgonimeton's development in the context of Alzheimer's disease treatment.
In other recent news, Athira Pharma's LIFT-AD clinical trial for fosgonimeton, a potential treatment for Alzheimer's disease, did not meet its primary endpoint. Despite this, the treatment showed consistent improvements across biomarkers associated with Alzheimer's disease, particularly in pre-specified subgroups of patients.
BTIG, after a detailed assessment of the trial results, downgraded Athira Pharma's stock from Buy to Neutral. The firm's analyst cited concerns over the drug's development path in a challenging and costly trial environment.
Additionally, Athira Pharma presented new preclinical data at the Alzheimer’s Association International Conference 2024, suggesting that fosgonimeton may reduce key Alzheimer’s disease-related protein pathology and protect neurons from amyloid-β toxicity.
In other developments, Athira has reached a preliminary settlement in a shareholder derivative lawsuit, which includes the implementation of corporate governance reforms and the coverage of legal fees and expenses.
InvestingPro Insights
As Athira Pharma (NASDAQ:ATHA) navigates the aftermath of its Phase 2 LIFT-AD study results, it's important to consider the company's financial health and market performance. According to InvestingPro data, Athira Pharma holds a market capitalization of $108.78 million, with a rather concerning P/E ratio of -0.96, reflecting its lack of profitability over the last twelve months as of Q2 2024. The company's stock price movements have been quite volatile, with a significant 15.98% return over the last three months, yet a notable decrease of 13.98% in the past week alone.
Two InvestingPro Tips that stand out in the context of Athira Pharma's current situation are the company's quick cash burn and its weak gross profit margins. These financial challenges are particularly relevant as the company decides on the future of fosgonimeton. Despite holding more cash than debt, the company's valuation implies a poor free cash flow yield. With analysts not expecting profitability this year, the financial runway and strategic decisions moving forward will be critical for investor confidence.
For those considering an investment in Athira Pharma, additional insights can be found on InvestingPro, which offers a total of 11 tips for the company, providing a more comprehensive view of its financial standing and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.